Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Given these encouraging findings, the researchers endeavored to test whether minimization of weight gain might translate to better quit outcomes for a population that is particularly concerned about gaining weight upon quitting.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

All participants received open label therapy with the nicotine patch for the first 8 weeks post-quit and behavioral counseling over the 27-week treatment.

The 2 pre-specified primary outcomes were change in weight for continuously abstinent participants and biologically verified end-of-treatment 7-day point-prevalence abstinence at 26 weeks after the quit date.

How the Study Was Run

The design is described as randomized, double-blind, open-label and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Everyone knew when Therapeutic nicotine (patch, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

What Was Measured

The subject headings attached to it are Administration, Cutaneous, Naltrexone, Nicotine, Smoking, Smoking Cessation and Weight Gain.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Drug and alcohol dependence), a journal based in Ireland.

More context: the Therapeutic nicotine (patch, non-peptide) compound page.